8-K: Avadel Pharmaceuticals Secures Orphan Drug Designation for LUMRYZ in Idiopathic Hypersomnia

Avadel Pharmaceuticals announced that its drug LUMRYZ has received Orphan Drug Designation from the FDA for the treatment of idiopathic hypersomnia, potentially offering significant benefits for patients with this rare sleep disorder.

Summary

• Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that LUMRYZ™ (sodium oxybate) for extended-release oral suspension has been granted Orphan Drug Designation (ODD) by the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH).
• The ODD was granted based on the plausible hypothesis that LUMRYZ may be clinically superior to existing drugs for the same indication, primarily due to its once-nightly dosing, which offers a major contribution to patient care for a chronic condition requiring potentially lifelong treatment.
• Idiopathic Hypersomnia is a rare and debilitating sleep disorder characterized by excessive daytime sleepiness not attributable to other medical conditions.
• LUMRYZ is currently being evaluated for IH in the pivotal Phase 3 REVITALYZ trial, a double-blind, placebo-controlled, randomized withdrawal, multicenter study designed to evaluate its efficacy and safety when given as a once-at-bedtime dose.
• The REVITALYZ trial aims to enroll approximately 150 adults and is on track for completion by year-end 2025.
• Orphan Drug Designation provides benefits such as eligibility for a seven-year period of market exclusivity in the U.S. following product approval, FDA assistance in clinical trial design, and exemption from FDA user fees.
• LUMRYZ is already FDA-approved for cataplexy or excessive daytime sleepiness (EDS) in adults (May 1, 2023) and pediatric patients 7 years and older (October 16, 2024) with narcolepsy, with 7 years of Orphan Drug Exclusivity granted for these indications due to its once-nightly dosing superiority over twice-nightly oxybate products.

Sentiment

Score: 8

Explanation: The granting of Orphan Drug Designation is a significant positive regulatory milestone for a new indication, offering substantial commercial benefits like market exclusivity and reduced development costs. It validates the drug's potential and the company's strategy in rare sleep disorders. While clinical trial success and approval are still pending, this designation de-risks the development pathway to some extent and enhances the drug's market potential.

Positives

• Receipt of Orphan Drug Designation (ODD) for LUMRYZ in Idiopathic Hypersomnia (IH) from the FDA, validating its potential for this rare disease.
• ODD provides significant potential benefits including 7 years of market exclusivity in the U.S. post-approval, FDA assistance in clinical trial design, and exemption from FDA user fees.
• LUMRYZ's once-nightly dosing regimen is considered a major contribution to patient care, especially for IH patients who suffer from profound sleep inertia, making it potentially superior to existing treatments.
• The pivotal Phase 3 REVITALYZ trial for IH is on track to be completed by year-end 2025, indicating good progress in its development.
• Avadel has an established commercial foundation in narcolepsy with LUMRYZ, which could facilitate a potential future launch for the IH indication.
• LUMRYZ is already approved for narcolepsy in adults (May 2023) and pediatric patients 7 years and older (October 2024), with existing Orphan Drug Exclusivity for these indications.

Negatives

• LUMRYZ is a controlled substance (GHB) with potential for abuse and misuse, requiring strict adherence to the LUMRYZ REMS program.
• Significant safety warnings are associated with LUMRYZ, including risks when taken with other central nervous system (CNS) depressants, which may cause serious medical problems like respiratory depression, low blood pressure, and death.
• Potential serious side effects include breathing problems (e.g., sleep apnea), mental health problems (e.g., confusion, hallucinations, depression, suicidal thoughts), and sleepwalking.
• LUMRYZ contains a high sodium content, which may not be suitable for patients on salt-restricted diets or those with high blood pressure, heart failure, or kidney problems.
• The drug can cause physical dependence and craving for the medicine when it is not taken as directed.

Risks

• Regulatory Risk: While ODD is granted, there is no guarantee of future FDA approval for LUMRYZ for the treatment of Idiopathic Hypersomnia.
• Clinical Trial Risk: The pivotal Phase 3 REVITALYZ trial may not demonstrate sufficient efficacy or safety for approval, or may face unforeseen delays in enrollment or completion.
• Commercialization Risk: Even if approved, successful commercialization for IH is not guaranteed and depends on market acceptance, competition, and payer coverage.
• Safety and Side Effects: LUMRYZ carries significant safety warnings, including risks of respiratory depression, mental health issues, and physical dependence, which could impact patient adoption or lead to post-market issues.
• Abuse Potential: As a controlled substance (GHB), LUMRYZ is subject to strict regulations (REMS program) and carries inherent risks of abuse and misuse.
• Sodium Content Risk: The high sodium content in LUMRYZ poses a risk for patients with certain pre-existing conditions such as hypertension, heart failure, or kidney problems.

Future Outlook

Avadel Pharmaceuticals expects to complete enrollment for the pivotal Phase 3 REVITALYZ trial for Idiopathic Hypersomnia by year-end 2025. The company aims to advance LUMRYZ in IH with the goal of transforming the IH treatment landscape, if approved, leveraging its established commercial foundation in narcolepsy.

Management Comments

• "We are pleased that LUMRYZ has been granted Orphan Drug Designation for the treatment of IH, and this recognition reinforces our strategy to develop differentiated therapies for patients with rare sleep disorders." Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals.
• "Receipt of ODD highlights the unique value of our next-generation, extended-release oxybate and its potential for IH patients, if approved." Greg Divis.
• "We continually hear from clinicians and patients of the substantial need for an extended-release oxybate for this patient population — a population who suffers from profound sleep inertia, making waking up in the middle of the night an even greater challenge than in narcolepsy." Greg Divis.
• "With continued progress in our pivotal Phase 3 REVITALYZ trial, an established commercial foundation in narcolepsy, and a relentlessly devoted team, we are well-positioned to advance LUMRYZ in IH with the goal of ultimately transforming the IH treatment landscape, if approved." Greg Divis.

Industry Context

The announcement positions Avadel as a key player in the rare sleep disorder market, specifically targeting Idiopathic Hypersomnia (IH), a condition with significant unmet needs. The focus on a once-nightly extended-release oxybate aims to differentiate LUMRYZ from existing treatments, addressing patient challenges like nocturnal arousal and profound sleep inertia common in IH. This aligns with a broader industry trend towards developing more convenient and patient-friendly formulations for chronic conditions.

Comparison to Industry Standards

• LUMRYZ is positioned as clinically superior to currently available, twice-nightly oxybate products due to its once-nightly dosing regimen, which avoids nocturnal arousal for a second dose.
• This once-nightly dosing is highlighted as a major contribution to patient care, particularly for IH patients who experience profound sleep inertia, making middle-of-the-night waking more challenging than for narcolepsy patients.
• The FDA previously granted 7 years of Orphan Drug Exclusivity to LUMRYZ for narcolepsy based on this clinical superiority finding over existing oxybate treatments.

Stakeholder Impact

• Shareholders: Positive impact due to expanded market potential for LUMRYZ, potential for increased revenue streams, and de-risking of the development pathway for a new indication.
• Patients (Idiopathic Hypersomnia): Potential for a new, more convenient (once-nightly) treatment option for a debilitating rare sleep disorder, addressing a significant unmet medical need.
• Clinicians: A new therapeutic option that could simplify treatment regimens for IH patients.
• Employees: Positive impact on morale and job security due to company growth and pipeline expansion.

Next Steps

• Continue enrollment and progress in the pivotal Phase 3 REVITALYZ trial for Idiopathic Hypersomnia.
• Complete enrollment for the REVITALYZ trial by year-end 2025.
• Seek potential FDA approval for LUMRYZ for the treatment of Idiopathic Hypersomnia following successful trial completion.
• Potentially commercialize LUMRYZ for Idiopathic Hypersomnia, if approved, leveraging existing commercial infrastructure for narcolepsy.

Key Dates

Recommendation

Keywords

Avadel Pharmaceuticals, LUMRYZ, Orphan Drug Designation, Idiopathic Hypersomnia, FDA, rare sleep disorders, sodium oxybate, REVITALYZ trial, Phase 3, biopharmaceutical, narcolepsy, extended-release